| AYTU BIOPHARMA, INC |
| Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | Q1-CY2014 | Q4-CY2013 |
| Balance Sheet Date | | | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | 2023-Sep-30 | 2023-Jun-30 | 2023-Mar-31 | 2022-Dec-31 | 2022-Sep-30 | 2022-Jun-30 | 2022-Mar-31 | 2021-Dec-31 | 2021-Sep-30 | 2021-Jun-30 | 2021-Mar-31 | 2020-Dec-31 | 2020-Sep-30 | | 2020-Mar-31 | 2019-Dec-31 | 2019-Sep-30 | | 2019-Mar-31 | 2018-Dec-31 | 2018-Sep-30 | 2018-Jun-30 | 2018-Mar-31 | 2017-Dec-31 | 2017-Sep-30 | 2017-Jun-30 | 2017-Mar-31 | 2016-Dec-31 | 2016-Sep-30 | 2016-Jun-30 | 2016-Mar-31 | 2015-Dec-31 | 2015-Sep-30 | 2015-Jun-30 | | 2014-Nov-30 | | 2014-May-31 | 2014-Feb-28 | 2013-Nov-30 |
| Fiscal Period | | | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q3-FY2023 | Q2-FY2023 | Q1-FY2023 | Q4-FY2022 | Q3-FY2022 | Q2-FY2022 | Q1-FY2022 | Q4-FY2021 | Q3-FY2021 | Q2-FY2021 | Q1-FY2021 | | Q3-FY2020 | Q2-FY2020 | Q1-FY2020 | | Q3-FY2019 | Q2-FY2019 | Q1-FY2019 | Q4-FY2018 | Q3-FY2018 | Q2-FY2018 | Q1-FY2018 | Q4-FY2017 | Q3-FY2017 | Q2-FY2017 | Q1-FY2017 | Q4-FY2016 | Q3-FY2016 | Q2-FY2016 | Q1-FY2016 | Q4-FY2015 | | Q1-FY2015 | | Q3-FY2014 | Q2-FY2014 | Q1-FY2014 |
| Operating Cash Flow | | | 2,803,000$ | (6,455,000$) | | | (788,000$) | (254,000$) | (135,000$) | (211,000$) | 9,365,000$ | (2,906,000$) | (2,440,000$) | (9,148,000$) | (7,095,000$) | (9,115,000$) | (8,822,000$) | (3,791,000$) | (6,277,000$) | (8,780,000$) | (2,924,000$) | (7,983,000$) | | 20,600,000$ | (6,099,237$) | (2,987,817$) | | (3,310,336$) | (4,302,680$) | (2,744,485$) | (4,543,340$) | (4,078,188$) | (3,100,986$) | (4,217,808$) | | | | | | | | | | | (9,327$) | | (14,415$) | (8,336$) | (6,858$) |
| Investing Cash Flow | | | (3,017,000$) | (69,000$) | | | (34,000$) | (45,000$) | (174,000$) | (76,000$) | (155,000$) | 1,000$ | (5,000$) | 42,000$ | (41,000$) | (70,000$) | (3,051,000$) | (86,000$) | (2,426,000$) | (317,000$) | (30,000$) | (9,000$) | | 343,903$ | (4,912,532$) | (1,042,103$) | | (105,590$) | (557,110$) | (303,177$) | (402,200$) | (69,897$) | | | | | | | | | | | | | | | | | |
| Financing Cash Flow | | | 12,993,000$ | 4,299,000$ | | | 1,068,000$ | 530,000$ | (126,000$) | (2,734,000$) | (5,404,000$) | 2,583,000$ | (1,865,000$) | 13,557,000$ | (1,117,000$) | 1,521,000$ | 6,590,000$ | (5,464,000$) | 11,814,000$ | (6,398,000$) | 27,076,000$ | (2,178,000$) | | 68,183,436$ | 9,258,350$ | 0$ | | 258,512$ | | 0$ | (23,730$) | 12,246,165$ | 0$ | 10,437,164$ | | | | | | | | | | | 16,008$ | | 23,200$ | 8,075$ | 5,441$ |
| End Cash Position | | | 30,952,000$ | 18,173,000$ | 20,398,000$ | 20,108,000$ | 20,006,000$ | 19,760,000$ | 19,529,000$ | 19,964,000$ | 22,985,000$ | 19,179,000$ | 19,501,000$ | 23,811,000$ | 19,360,000$ | 27,613,000$ | 35,277,000$ | 40,308,000$ | 49,649,000$ | 46,538,000$ | 62,033,000$ | 37,911,000$ | | 62,264,676$ | 5,259,492$ | 7,014,307$ | | 14,647,402$ | 17,804,887$ | 3,964,717$ | 7,012,527$ | 12,006,069$ | 3,908,183$ | 7,021,527$ | 802,328$ | 3,470,158$ | 5,230,394$ | 2,749,213$ | 8,054,190$ | 8,665,835$ | 10,959,546$ | 10,069,025$ | 7,353,061$ | | 1,051,575$ | 2,639,650$ | 4,121,044$ | | |
| Exchange Rate Effect | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Dividends Paid | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |